FASN and breast carcinoma: The collection was screened for cytotoxicity and FASN inhibition against a HER2-positive human breast cancer cell line overexpressing FASN, and three lead compounds were identified, G28, G37, and G56 (Figure 1c), which improved the properties of their precursor molecule EGCG without affecting mice body weight [21,22,23].